-- 
Argan, Sanofi, Stallergenes, Vinci: French Equity Preview

-- B y   J a m e s   H e r t l i n g   a n d   A n n e   S w a r d s o n
-- 
2011-10-04T04:00:02Z

-- http://www.bloomberg.com/news/2011-10-03/argan-sanofi-stallergenes-vinci-french-equity-preview.html
The following is a list of companies
whose shares may have unusual price changes in Paris. Stock
symbols are in parentheses after company names and prices are
from the last close.  France ’s benchmark  CAC 40 Index (CAC)  fell 1.9 percent to
2,926.83. The SBF120 Index decreased 1.9 percent to 2,236.80.  Argan (ARG)  : The warehouse owner raised its 2012
forecasts and said it’s studying a “significant” acquisition.
Shares fell 2.2 percent to 11.74 euros.  GDF Suez (GSZ)  : The utility completed the sale of its G6
Rete Gas unit in  Italy  to a group including Axa Private Equity,
Enel Distribution and F2i infrastructure fund, valued at 772
million euros ($1.02 billion). The shares fell 0.2 percent to
22.40 euros.  Sanofi (SAN FP): The company’s Genzyme unit is unable to
meet patient demand for the Fabrazyme drug for Fabry’s disease,
the company said in a statement. Cerezyme supply should begin to
improve in February, the company said. Shares fell 0.7 percent
to 49.01 euros.  Stallergenes SA (GENP)  : The pharmaceutical company said
Roberto Gradnik would become deputy chief executive officer and
the CEO next year, and chairman and CEO Albert Saporta would
become non-executive chairman. The shares fell 4.5 percent to
46.50 euros.  Vinci SA (DG)  : The builder and Hitachi Ltd. won a
contract to build the first phase of the Berjaya Central Park
residential and office complex in  Kuala Lumpur . The first phase
of the contract is worth 76 million euros, Vinci said. Shares
fell 1.9 percent to 31.80 euros.  To contact the reporters on this story:
James Hertling in Paris at 
 jhertling@bloomberg.net 
Anne Swardson at 
 aswardson@bloomberg.net   To contact the editor responsible for this story:
Vidya Root at 
 vroot@bloomberg.net  